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Background: The impact of sex steroids on bone health in transgender individuals is unclear.
Methods: A comprehensive search of several databases to 7 April 2015 was conducted for studies
evaluating bone health in transgender individuals receiving sex steroids. Pairs of reviewers selected
and appraised studies. A random effects model was used to pool weighted mean differences and
95% confidence intervals (CIs).
Results: Thirteen studies evaluating 639 transgender individuals were identified [392 male-to-
female (MTF), 247 female-to-male (FTM)]. In FTM individuals and compared with baseline values
before initiation of masculinizing hormone therapy, there was no statistically significant difference
in the lumbar spine, femoral neck, or total hip bonemineral density (BMD) when assessed at 12 and
24 months. In MTF individuals and compared with baseline values before initiation of feminizing
hormone therapy, there was a statistically significant increase in lumbar spine BMD at 12 months
(0.04 g/cm2; 95% CI, 0.03 to 0.06 g/cm2) and 24 months (0.06 g/cm2; 95% CI, 0.04 to 0.08 g/cm2).
Fracture rates were evaluated in a single cohort of 53MTF and 53 FTM individuals, with no events at
12 months. The body of evidence is derived mostly from observational studies at moderate risk
of bias.
Conclusion: In FTM individuals, masculinizing hormone therapy was not associated with significant
changes in BMD, whereas in MTF individuals feminizing hormone therapy was associated with an
increase in BMD at the lumbar spine. The impact of these BMD changes on patient-important
outcomes such as fracture risk is uncertain. (J Clin EndocrinolMetab 102: 3904–3913, 2017)
The precise number of individuals who experiencetranssexualism during their lifetime is uncertain;
however, a prevalence of 4.6 in 100,000 individuals
has been estimated (probably an underestimation)
(1, 2). The number of transgender individuals who seek
medical care appears to be increasing (3). Low-quality
evidence (i.e., which translates into low confidence
in the balance of risk and benefits) suggests that hor-
monal intervention to achieve desired secondary sexual
characteristics is beneficial in terms of psychological
functioning and overall quality of life (4). On the
other hand, unfavorable changes in lipid profile, with
unclear effects on cardiovascular outcomes, have been
reported (5).
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Many studies have established sex steroids (estrogen
and testosterone) as important regulators of bone health
both in men and women (6–8). In men, testosterone plays
an important role for male skeletal homeostasis, and a
minimal estradiol level is needed for optimal skeletal
maturation (7). In women, there is a positive net effect of
estrogen action on bone homeostasis, but the effect of
androgens is less clear (6, 8). This physiological back-
ground suggests that changes in bone health could be
expected as a result of sex steroid therapy.
The effect of sex steroids on the bone health of
transgender individuals has been scarcely studied, and
although clinical reviews about the topic are available,
a systematic evaluation and quantification of the effect
and potential clinical relevance when related to patient-
important outcomes (e.g., fracture risk) is not avail-
able (1, 9).
Clinicians taking care of transgender individuals
seeking sex steroid treatment need information about the
risks and benefits associated with therapy. In the case of
bone health, determining the degree and timing of ex-
pected changes in bone mineral density (BMD) or the
incidence of fractures could help identify the need for
follow-up and treatment considerations or provide re-
assurance if no detrimental effect is to be expected. To this
end, we performed a systematic review andmeta-analysis
of the available evidence assessing the effects of sex
steroid treatment on the bone health of transgender
individuals.
Methods
We performed a systematic review and meta-analysis to esti-
mate the impact of sex steroid treatment of adolescent and adult
transgender individuals on bone health. Outcomes of interest
were BMD and the incidence of fractures. This report followed
a systematic review protocol developed in collaboration with
experts from the Endocrine Society and the current standard for
reporting of systematic reviews (10).
Eligibility criteria
We included randomized trials, observational studies, and
case series of transsexual individuals who received sex steroids.
We included studies evaluating adolescents and adult trans-
gender individuals (gender-confirming surgery was not an ex-
clusion criterion). Eligible studies exposed natal men seeking
transition to the female sex [male-to-female (MTF)] to cross-sex
hormone therapy including estrogen, antiandrogens (cyproterone
acetate, spironolactone), or gonadotropin-releasing hormone
(GnRH) agonists and women seeking transition to the male sex
[female-to-male (FTM)] to testosterone. We included studies that
compared baseline values of BMD to posttherapy values in the
same individuals (treatment-naive patients, receiving therapy
for $3 months) or those that compared BMD values in the
transgender group (after$3 months of therapy) with a control or
reference group. Outcomes of interest included effects on bone
health (BMD at the lumbar spine, femoral neck, total hip, and
fractures).
We excluded studies in which the required information to
determine eligibility was not available in the published manu-
script and no response from the authors was obtained. We
included studies regardless of their publication status, language,
or size. Review articles, commentaries, and letters that did not
contain original data were excluded.
Study identification
A comprehensive search of several databases from 1980 to 7
April 2015 was conducted. Databases included Ovid Medline
In-Process & Other Non-Indexed Citations, Ovid Medline,
Ovid Embase, Ovid Cochrane Central Register of Controlled
Trials, and Scopus. An experienced librarian (L.J.P.) designed
the search strategy with input from study investigators with
expertise in conducting systematic reviews. Controlled vocab-
ulary supplemented with keywords was used to search for
studies of outcomes of hormone therapy on transgender in-
dividuals. The search strategy is available in the Supplemental
Appendix. We reviewed the reference list of narrative reviews
and consulted with experts to identify additional references.
The search results were uploaded into a systematic review
software (DistillerSR, Ottawa, Canada). Reviewers working
independently and in duplicate reviewed all abstracts and ti-
tles for inclusion (N.S.O., S.M., and R.R.G.). After abstract
screening and retrieval of potentially eligible studies, the full-
text publications were assessed for eligibility, with excellent
chance-adjusted interreviewer agreement (k statistic = 0.82).
Duplicate studies and studies with overlapping populations
were excluded. Disagreements were resolved by consensus
(the two reviewers discussed the discrepancy and reached a
decision).
Data collection and management
Reviewers working independently and in duplicate (N.S.O.,
S.M., and R.R.G.) using a standardized form collected the
following information from each eligible study: baseline clinical
features such as age, weight, body mass index, and group (MTF
or FTM); proportion of patients with gender confirmation
surgery and definition; type of intervention (medication, dose,
route, frequency) and duration of the exposure at the time of
outcome assessment; and outcomes (BMD, number of frac-
tures). We also extracted the definition of controls used in the
applicable studies. Disagreements were resolved by consensus.
Risk of bias assessment
We used the Newcastle Ottawa tool to evaluate the risk of
bias in observational studies. This tool evaluates the selection of
study cohorts, the comparability of the study cohorts, and the
ascertainment of exposure and outcomes (11). Reviewers working
independently assessed the risk of bias of included studies in du-
plicate. Any disagreements were resolved by consensus.
Author contact
To reduce reporting bias, we contacted by e-mail the cor-
responding authors (or any other author if we were not able to
reach the corresponding author) of each of the eligible studies in
which clarification or more information was needed to de-
termine eligibility or to complete analyses. We contacted seven
authors for clarification and to obtain further data; two replied.
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Table 1. Characteristics of Included Studies
Study Country Design Comparison Group Patients
No. of
Patients
Mean
Age Mean BMI
% of Patients
with GCS
Description of
Intervention
Duration of
Exposure
Dittrich et al.,
2005 (14)
Germany Cohort Same subjects
(before and after)
MTF 60 38.37 24.19a 0 3.8 mg goserelin
every 4 wk and
6 mg oral
estradiol-17
valerate per d.
24 mo
Klink et al.,
2015 (16)
The Netherlands Cohort Same subjects
(before and after)
MTF 15 14.9 20.3 100 Triptorelin 3.75 mg
every 4 wk SC
from 11.4–18.3 y.
GnRH 1.3 y (range,
0.5–3.8) and CSH
therapy 5.8 y
(range, 3.0–8.0)In the age range from
15.6 to 19 y
transgender
women were
prescribed
incremental
dosing of 17-
estradiol.
At a minimum age of
18 y, after
gonadectomy,
GnRH treatment
was terminated
and CSH therapy
continued.
Same subjects
(before and after)
FTM 19 15.0 20.9 100 Testosterone esters
(Sustanon 250mg/
mL) every 2–4 wk
in incremental
dosages.
GnRH 1.5 y (range,
0.25–5.2) and
CSH 5.4 y (range,
2.8–7.8)
At a minimum age of
18 y, after
gonadectomy,
GnRH treatment
was terminated
and CSH therapy
continued.
Mueller et al.,
2011 (18)
Germany Cohort Same subjects
(before and after)
MTF 84 36.3 22.3 0 3.8 mg goserelin
every 4 wk and
a dosage of 10 mg
estradiol 17-
valerate IM every
10 d.
24 mo
Mueller et al.,
2010 (17)
Germany Cohort Same subjects
(before and after)
FTM 45 30.4 24.1 0 Testosterone
undecanoate
1000 mg IM every
12 wk.
12 and 24 mo
Pelusi et al.,
2014 (19)
Italy Cohort Same subjects
(before and after)
FTM 15 30.9 NA 0 Testosterone
enanthate IM at
a dosage of
100 mg every 10
d (n = 15; TD
group).
12 mo
Same subjects
(before and after)
FTM 15 29.4 NA 0 Testosterone gel at
a dosage of 50mg/
d every evening.
12 mo
Same subjects
(before and after)
FTM 15 28.2 NA 0 Testosterone
undecanoate at
a dosage of
1000 mg at wk 0,
wk 6, and
thereafter, every
12 wk.
12 mo
Reutrakul et al.,
1998 (20)
Thailand Cohort Controls MTF 11 21.2 NA 0 Estradiol valerate
10mg per ampule,
mestranol 0.05mg
norethisterone 1
mg,or contraceptive
pills, ethinyl
estradiol, and
several doses of
levonorgestrel.
,24 mo
Controls MTF 17 24.1 NA 0 NA. .24 mo
Sosa et al.,
2003 (21)
Spain Cohort Controls MTF 27 43 26 0 Contraceptive pills
(ethinyl estradiol +
cyproterone
acetate or
levonorgestrel),
oral estrogen
(conjugated
equine), and depot
estrogens
(estradiol valerate
or mestranol +
norethisterone).
201mo (108)b (range
3–35 y)
(Continued)
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Table 1. Continued
Study Country Design Comparison Group Patients
No. of
Patients
Mean
Age Mean BMI
% of Patients
with GCS
Description of
Intervention
Duration of
Exposure
Turner et al.,
2004 (22)
USA Cohort Same subjects
(before and after)
FTM 8 33.1 NA 0 Testosterone IM
(mean dosage of
70.4 64.5 mg
weekly).
24 mo
Van Caenegem
et al., 2015 (24)
Belgium Cohort Same subjects
(before and after)
FTM 23 27 24.5 NA Testosterone
undecanoate of
1000 mg IM.
Injections were
administered at
baseline, after 6
and 18 wk, and
from then once
every 12 wk.
12 mo
Van Caenegem
et al., 2015 (23)
Belgium Cohort Same subjects
(before and after)
MTF 49 33 NA 0 Oral estradiol valerate,
4 mg daily or
transdermal 17-b
estradiol 100 mg/
24 h for patients
.45 years old or
both combined
with oral
cyproterone
acetate 50 mg
daily. Transdermal
estrogens were
used in older
transgender
women because
they carry a lower
thromboembolic
risk.
12 and 24 mo
van Kesteren et al.,
1996 (15)
The Netherlands Cohort Same subjects
(before and after)
MTF 56 33 22 0 Cyproterone acetate
100 mg/d with
ethinylestradiol or
transdermal
estradiol twice
a week.
12 mo
FTM 35 25 23 0 Testosterone esters
IM every 2 wk,
Sustanon 250, or
testosterone
undecanoate 160
mg/d orally.
12 mo
van Kesteren et al.,
1998 (25)
The Netherlands Cohort Same subjects
(before and after)
MTF 20 25.4 22.1 100 Cyproterone acetate
100 mg/d in
combination with
ethinylestradiol
100 mg/d until
gonadectomy;
after surgery just
estrogen to
maintain female
features.
45.5 mo (9.7)b
(range, 32–63)
Same subjects
(before and after)
FTM 19 25.0 22.1 100 Testosterone esters
250 mg/2 wk;
after gonadectomy
most patients
continued with IM
every 2–3 wk.
38.2 mo (8.6)b
(range, 28–53)
Wierckx et al.,
2014 (26)c
Belgium Cohort Same subjects (before
and after)/no
comparison
MTF 47 31.7 23.9 NA 50 mg cyproterone
acetate and 4 mg
estradiol valerate
daily, whereas
those .45 y old
received 50mg CA
daily together with
100 mg/24 h
transdermal 17-b
estradiol.
12 mo
Same subjects (before
and after)/no
comparison
MTF 6 19.3 22.9 NA 50 mg cyproterone
acetate and 4 mg
estradiol valerate
daily, whereas
those .45 y old
received 50mg CA
daily together with
100 mg/24 h
transdermal 17-b
estradiol.
12 mo
(Continued)
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Meta-analysis
We conducted random-effects meta-analysis by using the
DerSimonian–Laird random effects method to pool mean dif-
ferences for continuous outcomes and their associated 95%
confidence intervals (CIs) (12). Longitudinal and cross-sectional
studies were analyzed separately. We subtracted the baseline
BMD value (grams per square centimeter) from the follow-up
measurement when calculating the mean differences in BMD.
Therefore, negative values indicate a decrease from baseline and
positive values an increase. When comparing values against a
control group, we subtracted the control group BMD value
from the transgender group value, so a positive value in-
dicated higher value for the transgender group and a negative
value indicated a lower value for the transgender group. We
also estimated the proportion of patients with fractures in
the included studies. Inconsistency was assessed with the I2
statistic, with values ,25% indicating low and .75% in-
dicating high inconsistency (13). Analysis was conducted in
Stata Statistical Software: Release 14 (StataCorp LP, College
Station, TX).
Subgroups and sensitivity analyses
We planned to measure the difference in effect sizes between
subgroups based on population type (adolescent vs. adults),
different treatment regimens (e.g., oral vs. transdermal estrogen,
agonist alone vs. combination therapy), and outcome character-
istics (e.g., symptomatic vs. asymptomatic fractures). Sensitivity
analyses were conducted to explain possible inconsistencies across
study results.
Results
Study identification
A total of 391 potentially eligible articles were iden-
tified through our systematic database search, of which
13 were ultimately eligible (14–26), after exclusion of
studies that represented overlapping populations (27–30).
The complete study selection process is described in Sup-
plemental Fig. 1.
Across all studies, 639 transgender patients were in-
cluded in the analysis. These included 392 MTF indi-
viduals (9 studies) and 247 FTM participants (8 studies).
Twelve studies evaluated changes in BMD, and only 1
evaluated fracture rates.
A summary of the included studies is found in Table 1.
All the included studies were observational. Eleven
provided before- and after-treatment comparisons of the
same patients and 2 compared the results of transgender
individuals with those of controls. Only one study pro-
vided information on adolescent populations. The mean
age of transgender individuals in the included studies
ranged from 19 to 43 years. The treatment regimen of
MTF individuals included various doses of oral, trans-
dermal, or intramuscular (IM) estrogens and some reg-
imens included cyproterone acetate, GnRH agonists
(goserelin, triptorelin), spironolactone, or anastrozole.
Most FTM patients received IM preparations of testos-
terone and some transdermal or oral testosterone. Out-
come assessment was performed at 12 and 24 months in
the majority of the studies, although mean follow-up
times were provided in 3 studies.
Risk of bias
We judged the observational studies to be at moderate
risk of bias. The cohorts selected inmost studies appeared
to represent the totality of practice experience (as opposed
to selected cases), and outcomes were ascertained via se-
cured medical record review (Supplemental Table 1).
Meta-analysis
In FTM transgender individuals, meta-analysis showed
no statistically significant changes in the lumbar spine,
femoral neck, and total hip BMD at 12 and 24 months
after initiation of treatment comparedwith baseline values
(Fig. 1).
In theMTF group and compared with baseline values,
there was a statistically significant increase of BMD at 12
(0.04 g/cm2; 95%CI, 0.03 to 0.06 g/cm2) and 24months at
the lumbar spine (0.06 g/cm2; 95% CI, 0.04 to 0.08 g/cm2)
(Fig. 2). Changes in femoral neck BMD were not statis-
tically significant. The changes in BMD when the trans-
gender MTF group was compared with a control group
(genetic sex) were not statistically significant at the lumbar
spine or the femoral neck (Fig. 3).
Table 1. Continued
Study Country Design Comparison Group Patients
No. of
Patients
Mean
Age Mean BMI
% of Patients
with GCS
Description of
Intervention
Duration of
Exposure
Same subjects (before
and after)/no
comparison
FTM 27 27.3 24.5 NA Testosterone
undecanoate IM
every 3 mo.
12 mo
Same subjects (before
and after)/no
comparison
FTM 26 21.7 25.2 NA Testosterone
undecanoate IM
every 3 mo.
12 mo
Abbreviations: BMI, body mass index; CA, cyproterone acetate; CSH, cross-sex hormone; F, female; GCS, gender-confirming surgery; IM, intramuscular;
M, male; NA, not available; SC, subcutaneous.
aMedian.
bMean (standard deviation).
cStudy reporting fracture data.
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One study assessed fracture rates during follow-up. In
this study, 53 MTF and 53 FTM patients had no events
(fractures) for 12 months of follow-up (26). A single
study evaluated the effect of GnRH administration
(median of 1.3 years for theMTF group, 1.5 years for the
FTM group) and sex steroid therapy on adolescents and
found the BMDat the lumbar spine to be lower inMTF at
22 years of age when compared with baseline and a trend
to lower BMDvalues when comparedwith baseline in the
FTM group (16).
Subgroup and sensitivity analysis
We performed a sensitivity analysis of the change of
BMD in FTM individuals for studies where testoster-
one was administered only IM, without any changes in
the results compared with the main analysis (Supple-
mental Table 2). Because of inconsistent reporting, we
were unable to conduct the other preplanned subgroup
analyses.
Discussion
We performed a systematic review and meta-analysis to
summarize the effect of sex steroid therapy on the bone
health of transgender individuals. The effects of this
therapy on the rate of fractures were evaluated only in
a small study (53 MTF, 53 FTM) of short duration
(12 months of follow-up), with no fractures reported in
either of the two groups. Similarly, the effects of GnRH
agonists and sex steroids on the bone health of adoles-
cents were evaluated in only one study (16). The majority
of the available studies evaluated changes in BMD in
young individuals undergoing sex steroid therapy. In the
FTM individuals who received masculinizing therapy,
no statistically significant changes on BMD were found
when compared with baseline at the femoral neck,
lumbar spine, or total hip at 12 months or in the lumbar
spine or femoral neck after 24 months of therapy. These
results continued to be statistically nonsignificant when
Figure 1. Meta-analysis of BMD changes (g/cm2) in FTM individuals (compared to baseline values). ES, effect size; a positive value suggests
increase in BMD after receiving hormone therapy. TD, testosterone depot; TU, testosterone undeconoate.
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only studies including patients who received IM testos-
terone were analyzed. On the other hand, in MTF in-
dividuals who received feminizing therapy there was an
increase in BMD at the lumbar spine at both 12 and
24 months after therapy; no statistically significant changes
were noted in the femoral neck or total hip. The body of
evidence is derived from small observational studies of
short follow-up time at moderate risk of bias.
Strengths and limitations
We conducted an extensive search of the available
literature without any language restriction with the help
of a medical librarian, which decreases the chances of
missing studies addressing this clinical question (31). In
addition, we performed each step of the review in du-
plicate with good agreement. We attempted to decrease
the chances of reporting bias by contacting authors;
however, the response rate was low (32). The results of
the review were overall consistent across studies, yet we
were unable to performmost of our preplanned subgroup
analysis because the outcomes were not consistently re-
ported across different subgroups.
Implications for practice
Clinicians and transgender individuals benefit from
information that can clarify the benefits (e.g., overall
quality of life, psychological distress) and potential
harms of sex steroid therapy (e.g.,mortality, cancer risk,
bone health). Our findings suggest that in FTM in-
dividuals, masculinizing therapy is not associated with
significant changes in BMD 1 and 2 years after therapy
is initiated. On the other hand, in MTF individuals,
feminizing therapymay be associated with improvement
of BMD at the lumbar spine. However, because BMD
is a surrogate marker for overall bone health, the effect
of these findings on patient-important outcomes such as
fractures during long-term therapy remains unknown.
In addition, it is a challenge to determine the clinical
impact and relevance of BMD changes (because of
precision issues and variation in measurements and its
overall effect on fracture rates) (33, 34). For example,
BMD changes of 0.022 g/cm2 per year at the spine and
0.013 g/cm2 at the hip have been reported in post-
menopausal women and are considered significant (35).
Figure 2. Meta-analysis of BMD changes (g/cm2) in MTF individuals (compared to baseline values). ES, effect size; a positive value suggests
increase in BMD after receiving hormone therapy.
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In our analysis, the magnitude of BMD change in the
MTF group at the lumbar spine was found to be in
that range.
Implications for research
We have identified many clinical knowledge gaps
regarding the effects of sex steroid therapy on bone
health. First, there is paucity of data regarding fracture
rates in this population, and the studies evaluating BMD
changes have had a small number of individuals enrolled
and short follow-up times. Second, literature addressing
this clinical question in the pediatric and adolescent
population is lacking, with a single study evaluating the
effect of sex steroid treatment in this population. In
addition, the mean age of the individuals in the included
adult studies ranged from 19 to 43 years, suggesting that
cross-sex hormone therapy was started in many of these
patients in a window where their BMD could have been
increasing. Conducting research at low risk of bias in
this population can be challenging given the overall
barriers to care that these individuals face. However, it is
possible that the number of individuals seeking sex
steroid therapy in the future to alleviate their psycho-
logical burden will continue to increase. Therefore,
medical centers that provide care to these individuals
should make it a priority to conduct studies evaluating
patient-important outcomes during their long-term
follow-up, which will benefit both patients and their
clinicians (36).
Conclusion
Evidence from small observational studies with short-
term follow-up suggests that in FTM individuals sex
steroid therapy does not seem to be associated with
significant changes in BMD at 12 and 24 months after
initiation of therapy. In MTF individuals, sex steroid
therapy appears to be associated with increased BMD at
the lumbar spine at 12 and 24 months after initiation of
therapy. The impact of these BMD changes on patient-
important outcomes such as fracture risk remains
uncertain.
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